These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 25834048)
41. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Bartels T; Choi JG; Selkoe DJ Nature; 2011 Aug; 477(7362):107-10. PubMed ID: 21841800 [TBL] [Abstract][Full Text] [Related]
42. Physicochemical characterization of the G51D mutation of α-synuclein that is responsible for its severe cytotoxicity. Murata T; Tochio N; Utsunomiya-Tate N Neurosci Lett; 2021 Aug; 760():136077. PubMed ID: 34161822 [TBL] [Abstract][Full Text] [Related]
43. Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. Flagmeier P; Meisl G; Vendruscolo M; Knowles TP; Dobson CM; Buell AK; Galvagnion C Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10328-33. PubMed ID: 27573854 [TBL] [Abstract][Full Text] [Related]
44. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions. Gadhavi J; Patel M; Bhatia D; Gupta S Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997 [TBL] [Abstract][Full Text] [Related]
45. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. Wang X; Moualla D; Wright JA; Brown DR J Neurochem; 2010 May; 113(3):704-14. PubMed ID: 20141569 [TBL] [Abstract][Full Text] [Related]
46. Alpha-synuclein oligomers: a new hope. Bengoa-Vergniory N; Roberts RF; Wade-Martins R; Alegre-Abarrategui J Acta Neuropathol; 2017 Dec; 134(6):819-838. PubMed ID: 28803412 [TBL] [Abstract][Full Text] [Related]
47. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation. Chaari A; Eliezer D; Ladjimi M Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760 [TBL] [Abstract][Full Text] [Related]
48. DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers. Jin M; Matsumoto S; Ayaki T; Yamakado H; Taguchi T; Togawa N; Konno A; Hirai H; Nakajima H; Komai S; Ishida R; Chiba S; Takahashi R; Takao T; Hirotsune S Nat Commun; 2022 Nov; 13(1):6880. PubMed ID: 36371400 [TBL] [Abstract][Full Text] [Related]
49. Cofilin 1 promotes the aggregation and cell-to-cell transmission of α-synuclein in Parkinson's disease. Yan M; Meng L; Dai L; Zhang X; Chen G; Zheng Y; Zha Y; Zeng Y; Zhang Z Biochem Biophys Res Commun; 2020 Sep; 529(4):1053-1060. PubMed ID: 32819564 [TBL] [Abstract][Full Text] [Related]
50. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
51. Parkinson's disease-linked V15A mutation facilitates α-synuclein aggregation by reducing membrane affinity. Buratti FA; Fernández CO; Zweckstetter M Protein Sci; 2023 Aug; 32(8):e4693. PubMed ID: 37358478 [TBL] [Abstract][Full Text] [Related]
52. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Forloni G; Bertani I; Calella AM; Thaler F; Invernizzi R Ann Neurol; 2000 May; 47(5):632-40. PubMed ID: 10805334 [TBL] [Abstract][Full Text] [Related]
53. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724 [TBL] [Abstract][Full Text] [Related]
54. Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein. Lashuel HA; Novello S Neurobiol Dis; 2021 Aug; 156():105417. PubMed ID: 34102275 [TBL] [Abstract][Full Text] [Related]
55. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein. Maor G; Rapaport D; Horowitz M Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125 [TBL] [Abstract][Full Text] [Related]
56. Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. Choi MG; Kim MJ; Kim DG; Yu R; Jang YN; Oh WJ PLoS One; 2018; 13(4):e0195339. PubMed ID: 29608598 [TBL] [Abstract][Full Text] [Related]
57. Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model. Lu J; Sun F; Ma H; Qing H; Deng Y Biochem Biophys Res Commun; 2015 Sep; 464(4):988-993. PubMed ID: 26192120 [TBL] [Abstract][Full Text] [Related]
58. Initiation and propagation of α-synuclein aggregation in the nervous system. Hijaz BA; Volpicelli-Daley LA Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659 [TBL] [Abstract][Full Text] [Related]
59. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839 [TBL] [Abstract][Full Text] [Related]